ArticleFood technology and biotechnology
Effect of
Article in Food technology and biotechnology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Research background: Global food security faces increasing threats from chemical contaminants, with N-nitrosodiethylamine (NDEA) emerging as a potent hepatotoxicant of significant concern. NDEA-induced hepatic injury causes a pathological triad: ( Experimental approach: The hepatoprotective and microbiota-modulating efficacy of extracellular polyphenols from Results and conclusions: After 28-day oral administration (50-100 (mg/kg)/day), LSP156 significantly improved somatic growth parameters (body mass gain) and organ indices in NDEA-induced mice. LSP156 increased the activities of SOD and catalase, as well as glutathione levels, and greatly reduced the liver function markers alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase and total bilirubin. It also improved liver cell damage in tissue samples compared to model controls. LSP156 halted the activation of STAT3 and reduced TLR4 levels, which lowered cyclooxygenase protein levels and protected the liver from damage. LSP156 enhanced the digestion and absorption of carbohydrates and proteins, as well as the biosynthesis of terpenoids such as ubiquinone in mice, by rectifying intestinal flora imbalances, modifying the flora structure and demonstrating a strong correlation between Novelty and scientific contribution: Fungal polyphenol LSP156 maintains balanced gut bacteria by simultaneously managing inflammation and oxidation. These findings suggest a new approach to designing drugs that target multiple factors in complex metabolic disorders.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.